Incanthera plc

AQSE Growth Market -
The Company is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and is currently being prepared for licensing to a commercial partner within 12-18 months.

The Company originated from the Institute of Cancer Therapeutics – University of Bradford and, in addition to Sol, has acquired and developed a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

Symbol Ccy Code Bid Ask Share Price (Mid) Previous Close Volume Last Traded
INC GBX 6.8 7.1 6.95 6.95 100000 03.01.23

MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.

Key Information

Market Cap: £5,308,759
Inst Type:Ordinaries
Tradable securities in issue:76,385,028
% daily price change:0.00%

Latest Trades

Date & Time Volume Price
03.01.23  |  11:04:511000004
02.12.22  |  14:57:2150006.8
11.10.22  |  09:34:29100006.5
26.09.22  |  09:06:00136006.2
07.09.22  |  08:06:27416674
05.09.22  |  10:42:3563186.8
02.09.22  |  10:21:36500006.5
31.08.22  |  08:34:31208335
29.07.22  |  12:17:53100006.5
27.07.22  |  14:56:3013596.92

Latest Announcements

Date & Time Title
07.12.22  |  07:00:00Incanthera PLC - Half-year Report
27.09.22  |  12:58:00Incanthera PLC - Result of AGM
27.09.22  |  08:17:00Incanthera PLC - Issue of Equity
02.09.22  |  07:01:00Incanthera PLC - Notice of AGM and Posting of Accounts
02.09.22  |  07:00:00Incanthera PLC - Final Results
23.02.22  |  07:00:00Incanthera PLC - Directorate Change
06.12.21  |  07:00:00Incanthera PLC - Half-year Report
27.09.21  |  07:00:00Incanthera PLC - Filing of Trademark Applications
21.09.21  |  07:00:00Incanthera PLC - Company Presentation at Hardman Lifescience Forum
23.06.21  |  12:59:00Incanthera PLC - Result of AGM


Business Address

Incanthera plc, 76 King Street, Manchester, M2 4NH, United Kingdom.


Phone: +44 (0) 161 817 5005

Registered Address

76 King Street, Manchester, M2 4NH, United Kingdom.


Corporate Adviser

Cairn Financial Advisers LLP., 9th Floor, 107 Cheapside, London, United Kingdom.

Phone: +44 (0)20 7213 0880


Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom.


Phone: +44 (0) 121 585 1131